Effect of Additional Clostridium butyricum on the Intestinal Flora of Chronic Hepatitis B Patients Treated with Entecavir

被引:5
|
作者
Lu, Yu-Xia [1 ]
Chang, Yi-Zhong [1 ]
Liang, Ping [2 ]
Yang, Chang-Qing [1 ]
机构
[1] Tongji Univ, Tongji Hosp, Inst Digest Dis, Dept Infect Dis,Dept Gastroenterol & Hepatol,Sch, 389 Xin Cun Rd, Shanghai 200065, Peoples R China
[2] Tongji Univ, Tongji Hosp, Dept Lab Med, Sch Med, 389 Xin Cun Rd, Shanghai 200065, Peoples R China
基金
中国国家自然科学基金;
关键词
Chronic viral hepatitis B; Clostridium butyricum; Entecavir; Intestinal microflora; GUT-LIVER AXIS; MICROBIOTA; CIRRHOSIS; PATHOGENESIS; DISEASES;
D O I
10.1007/s40121-021-00463-1
中图分类号
R51 [传染病];
学科分类号
100401 ;
摘要
Introduction To explore the influence of intestinal flora on the occurrence, development and antiviral therapy of chronic hepatitis B (CHB), 16S rDNA amplification sequencing was performed to investigate the intestinal flora in CHB patients treated with entecavir (ETV) and Clostridium butyricum (CB). Methods CHB patients were divided into the ETV group (treatment with ETV alone) and ETV + CB group (treatment with ETV and CB). After 8-week treatment, feces samples were collected and processed for 16S rDNA amplicon sequencing; blood samples were collected for the biochemical, immunologic and virologic evaluations, which were compared between groups. Results ETV treatment for 8 weeks significantly decreased the serum levels of alanine aminotransferase (ALT), interleukin-6 (IL-6), IL-8, tumor necrosis factor-alpha (TNF-alpha) and HBV DNA compared to those before treatment, but there were no marked differences between the ETV group and ETV + CB group. The intestinal flora changed significantly in the CHB patients after ETV + CB treatment: there were marked differences in 13 unique species before treatment and 4 unique species after ETV + CB treatment; at the phylum level, the top five bacteria with significant difference between patients before treatment and ETV + CB patients were Firmicutes, Actinobacteria, Cyanobacteria, Euryarchaeota and Synergistetes. There were significant differences in 25 unique species in the ETV group and 4 unique species in the ETV + CB group; at the phylum level, the top five bacteria with significant difference between ETV patients and ETV + CB patients were Actinobacteria, Fusobacteria, Proteobacteria, Saccharibacteria and Synergistetes. Conclusion ETV treatment improves the serum biochemical, immunologic and virologic variables, but additional CB fails to further improve these variables. Of note, additional CB affects the intestinal flora in the CHB patients treated with ETV.
引用
收藏
页码:1519 / 1530
页数:12
相关论文
共 50 条
  • [21] Clinical utility of entecavir for chronic hepatitis B in Chinese patients
    Wang, Jiyao
    DRUG DESIGN DEVELOPMENT AND THERAPY, 2014, 8 : 13 - 24
  • [22] Effect of Clostridium butyricum on fecal flora in Helicobacter pylori eradication therapy
    Izumi Shimbo
    Taketo Yamaguchi
    Takeo Odaka
    Kenichi Nakajima
    Akinori Koide
    Hidehiko Koyama
    Hiromitsu Saisho
    World Journal of Gastroenterology, 2005, (47) : 7520 - 7524
  • [23] Effect of Clostridium butyricum on fecal flora in Helicobacter pylori eradication therapy
    Shimbo, Izumi
    Yamaguchi, Taketo
    Odaka, Takeo
    Nakajima, Kenichi
    Koide, Akinori
    Koyama, Hidehiko
    Saisho, Hiromitsu
    WORLD JOURNAL OF GASTROENTEROLOGY, 2005, 11 (47) : 7520 - 7524
  • [24] A novel evidence of serial changes of bone mineral density in chronic hepatitis B patients treated with entecavir
    Pao-Yuan Huang
    Sherry Yueh-Hsia Chiu
    Kuo-Chin Chang
    Po-Lin Tseng
    Yi-Hao Yen
    Ming-Chao Tsai
    Jing-Houng Wang
    Kwong-Ming Kee
    Chien-Hung Chen
    Chao-Hung Hung
    King-Wah Chiu
    Tsung-Hui Hu
    Hepatology International, 2021, 15 : 310 - 317
  • [25] No difference in hepatocellular carcinoma risk between chronic hepatitis B patients treated with entecavir versus tenofovir
    Su, Feng
    Berry, Kristin
    Ioannou, George N.
    GUT, 2021, 70 (02) : 370 - 378
  • [26] A novel evidence of serial changes of bone mineral density in chronic hepatitis B patients treated with entecavir
    Huang, Pao-Yuan
    Chiu, Sherry Yueh-Hsia
    Chang, Kuo-Chin
    Tseng, Po-Lin
    Yen, Yi-Hao
    Tsai, Ming-Chao
    Wang, Jing-Houng
    Kee, Kwong-Ming
    Chen, Chien-Hung
    Hung, Chao-Hung
    Chiu, King-Wah
    Hu, Tsung-Hui
    HEPATOLOGY INTERNATIONAL, 2021, 15 (02) : 310 - 317
  • [27] Validation of risk prediction scores for hepatocellular carcinoma in patients with chronic hepatitis B treated with entecavir or tenofovir
    Chang, Jin Won
    Lee, Jae Seung
    Lee, Hye Won
    Kim, Beom Kyung
    Park, Jun Yong
    Kim, Do Young
    Ahn, Sang Hoon
    Seo, Yeon Seok
    Lee, Han Ah
    Kim, Mi Na
    Lee, Yu Rim
    Hwang, Seong Gyu
    Rim, Kyu Sung
    Um, Soon Ho
    Tak, Won Young
    Kweon, Young Oh
    Park, Soo Young
    Kim, Seung Up
    JOURNAL OF VIRAL HEPATITIS, 2021, 28 (01) : 95 - 104
  • [28] Baseline hepatitis B surface antigen quantitation can predict virologic response in entecavir-treated chronic hepatitis B patients
    Wang, Chia-Chi
    Tseng, Tai-Chung
    Wang, Pin-Chao
    Lin, Hans Hsienhong
    Kao, Jia-Horng
    JOURNAL OF THE FORMOSAN MEDICAL ASSOCIATION, 2014, 113 (11) : 786 - 793
  • [29] Association of KIR Genotypes and Haplotypes in HBeAg-positive Chronic Hepatitis B Patients Treated with Entecavir
    Zhuang, YunLong
    Li, XiXi
    Li, Xiaohua
    Xu, HuiCong
    Ye, Hui
    Sun, Di
    Liu, XiangZhong
    Ren, GuiJie
    IMMUNOLOGICAL INVESTIGATIONS, 2019, 48 (04) : 333 - 344
  • [30] Viral load and alanine aminotransferase correlate with serologic response in chronic hepatitis B patients treated with entecavir
    Wang, Chia-Chi
    Tseng, Kuo-Chih
    Peng, Cheng-Yuan
    Hsieh, Tsai-Yuan
    Lin, Chih-Lin
    Su, Tung-Hung
    Tseng, Tai-Chung
    Hsu, Ching-Sheng
    Lin, Hans Hsienhong
    Kao, Jia-Horng
    JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 2013, 28 (01) : 46 - 50